BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lam AM, Ren S, Espiritu C, Kelly M, Lau V, Zheng L, Hartman GD, Flores OA, Klumpp K. Hepatitis B Virus Capsid Assembly Modulators, but Not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA Variants. Antimicrob Agents Chemother. 2017;61. [PMID: 28559265 DOI: 10.1128/aac.00680-17] [Cited by in Crossref: 39] [Cited by in F6Publishing: 18] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Hartman GD, Kuduk SD, Espiritu C, Lam AM. P450s under Restriction (PURE) Screen Using HepaRG and Primary Human Hepatocytes for Discovery of Novel HBV Antivirals. ACS Med Chem Lett 2020;11:1919-27. [PMID: 33062174 DOI: 10.1021/acsmedchemlett.9b00630] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Choi HSJ, Tonthat A, Janssen HLA, Terrault NA. Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B. Hepatol Commun 2021. [PMID: 34894108 DOI: 10.1002/hep4.1875] [Reference Citation Analysis]
3 Mani N, Cole AG, Phelps JR, Ardzinski A, Cobarrubias KD, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Guo H, Guo JT, Harasym TO, Kadhim S, Kultgen SG, Lee ACH, Li AHL, Long Q, Majeski SA, Mao R, McClintock KD, Reid SP, Rijnbrand R, Snead NM, Micolochick Steuer HM, Stever K, Tang S, Wang X, Zhao Q, Sofia MJ. Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation. Antimicrob Agents Chemother. 2018;62:e00082-18. [PMID: 29555628 DOI: 10.1128/aac.00082-18] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
4 Lim CS, Sozzi V, Littlejohn M, Yuen LKW, Warner N, Betz-Stablein B, Luciani F, Revill PA, Brown CM. Quantitative analysis of the splice variants expressed by the major hepatitis B virus genotypes. Microb Genom 2021;7. [PMID: 33439114 DOI: 10.1099/mgen.0.000492] [Reference Citation Analysis]
5 Niklasch M, Zimmermann P, Nassal M. The Hepatitis B Virus Nucleocapsid-Dynamic Compartment for Infectious Virus Production and New Antiviral Target. Biomedicines 2021;9:1577. [PMID: 34829806 DOI: 10.3390/biomedicines9111577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hadziyannis E, Laras A. Viral Biomarkers in Chronic HBeAg Negative HBV Infection. Genes (Basel) 2018;9:E469. [PMID: 30262738 DOI: 10.3390/genes9100469] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
7 Lahlali T, Berke JM, Vergauwen K, Foca A, Vandyck K, Pauwels F, Zoulim F, Durantel D. Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle. Antimicrob Agents Chemother 2018;62:e00835-18. [PMID: 30012770 DOI: 10.1128/AAC.00835-18] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 9.3] [Reference Citation Analysis]
8 van Campenhout MJH, van Bömmel F, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Berg T, Hansen BE, Janssen HLA. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. J Viral Hepat 2020;27:610-9. [PMID: 32052503 DOI: 10.1111/jvh.13272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
9 Fukutomi K, Hikita H, Murai K, Nakabori T, Shimoda A, Fukuoka M, Yamai T, Higuchi Y, Miyakawa K, Suemizu H, Ryo A, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T. Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus-Infected Hepatocytes During Interferon Administration. Hepatol Commun 2021. [PMID: 34558845 DOI: 10.1002/hep4.1804] [Reference Citation Analysis]
10 Gane EJ, Schwabe C, Berliba E, Tangkijvanich P, Jucov A, Ghicavii N, Verbinnen T, Lenz O, Talloen W, Kakuda TN, Westland C, Patel M, Yogaratnam JZ, Dragone L, Van Remoortere P. Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection. J Antimicrob Chemother 2022:dkab491. [PMID: 35040959 DOI: 10.1093/jac/dkab491] [Reference Citation Analysis]
11 Hu J, Cheng J, Tang L, Hu Z, Luo Y, Li Y, Zhou T, Chang J, Guo JT. Virological Basis for the Cure of Chronic Hepatitis B. ACS Infect Dis 2019;5:659-74. [PMID: 29893548 DOI: 10.1021/acsinfecdis.8b00081] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
12 Ghosh S, Chakraborty A, Banerjee S. Persistence of Hepatitis B Virus Infection: A Multi-Faceted Player for Hepatocarcinogenesis. Front Microbiol 2021;12:678537. [PMID: 34526974 DOI: 10.3389/fmicb.2021.678537] [Reference Citation Analysis]
13 Zhang Y, Zhang H, Zhang J, Zhang J, Guo H. Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate. Antiviral Res 2019;165:47-54. [PMID: 30902704 DOI: 10.1016/j.antiviral.2019.03.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
14 Helsen N, Vervoort T, Vandenbossche J, Lenz O, Monshouwer M, Pauwels F, Snoeys J. Effect of Plasma Protein Binding on the Anti-Hepatitis B Virus Activity and Pharmacokinetic Properties of NVR 3-778. Antimicrob Agents Chemother 2018;62:e01497-18. [PMID: 30181376 DOI: 10.1128/AAC.01497-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
15 Lam AM, Espiritu C, Vogel R, Ren S, Lau V, Kelly M, Kuduk SD, Hartman GD, Flores OA, Klumpp K. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus. Antimicrob Agents Chemother 2019;63:e01734-18. [PMID: 30373799 DOI: 10.1128/AAC.01734-18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
16 Liu Y, Veeraraghavan V, Pinkerton M, Fu J, Douglas MW, George J, Tu T. Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence. Front Microbiol 2021;12:665201. [PMID: 34194408 DOI: 10.3389/fmicb.2021.665201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Nair S, Li L, Francis S, Turner WW, VanNieuwenhze M, Zlotnick A. Use of a Fluorescent Analogue of a HBV Core Protein-Directed Drug To Interrogate an Antiviral Mechanism. J Am Chem Soc 2018;140:15261-9. [PMID: 30375863 DOI: 10.1021/jacs.8b07988] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
18 Shen S, Xie Z, Cai D, Yu X, Zhang H, Kim ES, Zhou B, Hou J, Zhang X, Huang Q, Sun J, Guo H. Biogenesis and molecular characteristics of serum hepatitis B virus RNA. PLoS Pathog 2020;16:e1008945. [PMID: 33079954 DOI: 10.1371/journal.ppat.1008945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Liu S, Zhou B, Valdes JD, Sun J, Guo H. Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology 2019;69:1816-27. [PMID: 30362148 DOI: 10.1002/hep.30325] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 18.7] [Reference Citation Analysis]
20 Sagnelli C, Sagnelli E. Towards the worldwide eradication of hepatitis B virus infection: A combination of prophylactic and therapeutic factors. World J Clin Infect Dis 2019; 9(2): 11-22 [DOI: 10.5495/wjcid.v9.i2.11] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Bai L, Zhang X, Kozlowski M, Li W, Wu M, Liu J, Chen L, Zhang J, Huang Y, Yuan Z. Extracellular Hepatitis B Virus RNAs Are Heterogeneous in Length and Circulate as Capsid-Antibody Complexes in Addition to Virions in Chronic Hepatitis B Patients. J Virol 2018;92:e00798-18. [PMID: 30282709 DOI: 10.1128/JVI.00798-18] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
22 Kim H, Ko C, Lee JY, Kim M. Current Progress in the Development of Hepatitis B Virus Capsid Assembly Modulators: Chemical Structure, Mode-of-Action and Efficacy. Molecules 2021;26:7420. [PMID: 34946502 DOI: 10.3390/molecules26247420] [Reference Citation Analysis]
23 Wei XF, Gan CY, Cui J, Luo YY, Cai XF, Yuan Y, Shen J, Li ZY, Zhang WL, Long QX, Hu Y, Chen J, Tang N, Guo H, Huang AL, Hu JL. Identification of Compounds Targeting Hepatitis B Virus Core Protein Dimerization through a Split Luciferase Complementation Assay. Antimicrob Agents Chemother 2018;62:e01302-18. [PMID: 30224531 DOI: 10.1128/AAC.01302-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]